Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results

 Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013
                         Unaudited Financial Results

PR Newswire

BEIJING, March 12, 2014

BEIJING, March 12, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a
leading provider of biopharmaceutical products in China, today announced that
it will release its unaudited financial results for the fourth quarter and
whole year ended December 31, 2013, after market closes on Wednesday, March
19, 2014 EDT.The Company will host a conference call prior to the market
opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20,
2014 at 8:00 p.m. China Standard Time) to review the Company's financial
results and provide an update on recent corporate developments.

To access the conference call, please dial 1-877-407-0784 (USA) or
1-201-689-8560 (International).A replay of the call will be available from 11
a.m. EDT on March 20, 2014, to April 3, 2014, at midnight. To access the
replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and
reference the replay pin number 13578265.

A live audio webcast of the call will also be available from the investors
section on the corporate web site at webcast replay can be
accessed on the corporate website beginning March 20, 2014, and the replay
will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses
on the research, development, manufacturing and commercialization of vaccines
that protect against human infectious diseases including hepatitis A and B,
seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine
flu) and mumps, as well as animal rabies vaccine for canines. The Company
recently concluded the phase III clinical trial for enterovirus 71 (against
hand, foot and mouth disease) and filed the new drug application with China
Food & Drug Administration. In 2009, Sinovac was the first company worldwide
to receive approval for its H1N1 influenza vaccine, Panflu.1, and has
manufactured it for the Chinese Central Government, pursuant to the
government-stockpiling program. The Company is also the only supplier of the
H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac
is developing a number of new pipeline vaccines including vaccines for
pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella.
Sinovac sells its vaccines mainly in China and exports selected vaccines to
Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license
to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are
made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel: +86-10-8279-9659/9696
Fax: +86-10-6296-6910

Stephanie Carrington
The Ruth Group
Tel: +1-646-536-7017

Aaron Estrada
The Ruth Group
Tel: +1-646-536-7028

SOURCE Sinovac Biotech Ltd.

Press spacebar to pause and continue. Press esc to stop.